Elbasvir/grazoprevir

Drug Profile

Elbasvir/grazoprevir

Alternative Names: Elbasvir and grazoprevir; Grazoprevir/elbasvir; MK-5172/MK-8742; MK-5172A; MK-8742/MK-5172; ZEPATIER

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Amides; Antivirals; Benzoxazines; Carbamates; Carboxylic acids; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Macrocyclic compounds; Pyrrolidines; Quinoxalines; Small molecules; Sulfones
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 02 Jun 2017 University of Pennsylvania and Merck initiates enrolment in a phase I/II trial for Hepatitis C in USA (NCT03146741)
  • 10 Apr 2017 Merck completes the phase III C-CORAL trial in Hepatitis C (Treatment-naive) in China, South Korea, Taiwan, Vietnam, Thailand, Australia, and Russia (PO) (NCT02251990)
  • 02 Feb 2017 Launched for Hepatitis C (Treatment-naive, Treatment-experienced) in Japan and United Kingdom (PO) before February 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top